In reply

Vinay Prasad; Victoria Kaestner; Sham Mailankody

doi:10.1001/jamaoncol.2018.1715

In reply

Vinay Prasad, Victoria Kaestner, Sham Mailankody

Knight Cancer Institute

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1300-1301
Number of pages	2
Journal	JAMA Oncology
Volume	4
Issue number	9
DOIs	https://doi.org/10.1001/jamaoncol.2018.1715
State	Published - Sep 2018

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2018.1715

Cite this

@article{593240124696416f8afe0790cc29efbf,

title = "In reply",

author = "Vinay Prasad and Victoria Kaestner and Sham Mailankody",

note = "Funding Information: Conflict of Interest Disclosures: Dr Richardson has received honoraria for advisory boards from Genentech and AstraZeneca. Dr Coleman has grant support from Roche/Genentech, AstraZeneca, Clovis, AbbVie, Merck, and Janssen. No other disclosures are reported. 1. Richardson DL, Sill MW, Coleman RL, et al. Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2018;4(2):196-202. doi:10.1001/jamaoncol.2017.4218 2. Pignata S, Lorusso D, Scambia G, et al; MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16(5):561-568. doi:10.1016/S1470-2045(15)70115-4 3. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-1308. doi:10.1200/JCO.2013.51.4489 4. Osman MA, Elkady MS, Nasr KE. Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clin Med Insights Oncol. 2016;10:35-41. doi:10.4137/CMO.S38204 Funding Information: Conflict of Interest Disclosures: Dr Prasad reports receiving royalties from his book Ending Medical Reversal, that his work is funded by the Laura and John Arnold Foundation, and that he has received honoraria for Grand Rounds/ lectures from several universities, medical centers, and professional societies. Dr Mailankody is a clinical investigator on clinical trials supported by Juno Therapeutics, Janssen Oncology, and Takeda Oncology. No other disclosures are reported.",

year = "2018",

month = sep,

doi = "10.1001/jamaoncol.2018.1715",

language = "English (US)",

volume = "4",

pages = "1300--1301",

journal = "JAMA oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "9",

}

TY - JOUR

T1 - In reply

AU - Prasad, Vinay

AU - Kaestner, Victoria

AU - Mailankody, Sham

N1 - Funding Information: Conflict of Interest Disclosures: Dr Richardson has received honoraria for advisory boards from Genentech and AstraZeneca. Dr Coleman has grant support from Roche/Genentech, AstraZeneca, Clovis, AbbVie, Merck, and Janssen. No other disclosures are reported. 1. Richardson DL, Sill MW, Coleman RL, et al. Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2018;4(2):196-202. doi:10.1001/jamaoncol.2017.4218 2. Pignata S, Lorusso D, Scambia G, et al; MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16(5):561-568. doi:10.1016/S1470-2045(15)70115-4 3. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-1308. doi:10.1200/JCO.2013.51.4489 4. Osman MA, Elkady MS, Nasr KE. Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clin Med Insights Oncol. 2016;10:35-41. doi:10.4137/CMO.S38204 Funding Information: Conflict of Interest Disclosures: Dr Prasad reports receiving royalties from his book Ending Medical Reversal, that his work is funded by the Laura and John Arnold Foundation, and that he has received honoraria for Grand Rounds/ lectures from several universities, medical centers, and professional societies. Dr Mailankody is a clinical investigator on clinical trials supported by Juno Therapeutics, Janssen Oncology, and Takeda Oncology. No other disclosures are reported.

PY - 2018/9

Y1 - 2018/9

UR - http://www.scopus.com/inward/record.url?scp=85053411864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053411864&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2018.1715

DO - 10.1001/jamaoncol.2018.1715

M3 - Letter

AN - SCOPUS:85053411864

VL - 4

SP - 1300

EP - 1301

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

IS - 9

ER -